Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 84

1.

Mechanisms of simvastatin myotoxicity: The role of autophagy flux inhibition.

Emami A, Shojaei S, da Silva Rosa SC, Aghaei M, Samiei E, Vosoughi AR, Kalantari F, Kawalec P, Thliveris J, Sharma P, Zeki AA, Akbari M, Gordon JW, Ghavami S.

Eur J Pharmacol. 2019 Aug 23;862:172616. doi: 10.1016/j.ejphar.2019.172616. [Epub ahead of print]

PMID:
31449810
2.

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries.

Malinowski KP, Kawalec P, Trąbka W, Czech M, Petrova G, Manova M, Savova A, Draganić P, Vostalová L, Slabý J, Männik A, Márky K, Rugaja Z, Gulbinovic J, Tesar T, Paveliu MS.

Front Pharmacol. 2019 May 8;10:487. doi: 10.3389/fphar.2019.00487. eCollection 2019.

3.

Coffee consumption and colorectal cancer risk: a dose-response meta-analysis on prospective cohort studies.

Micek A, Gniadek A, Kawalec P, Brzostek T.

Int J Food Sci Nutr. 2019 Mar 28:1-21. doi: 10.1080/09637486.2019.1591352. [Epub ahead of print]

PMID:
30922134
4.

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib.

Kawalec P, Śladowska K, Malinowska-Lipień I, Brzostek T, Kózka M.

Ther Clin Risk Manag. 2019 Feb 13;15:275-284. doi: 10.2147/TCRM.S192440. eCollection 2019. Review.

5.

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.

Malinowski KP, Kawalec P, Trabka W, Sowada C, Pilc A.

Front Pharmacol. 2018 Nov 12;9:1263. doi: 10.3389/fphar.2018.01263. eCollection 2018.

6.

Autophagy modulates temozolomide-induced cell death in alveolar Rhabdomyosarcoma cells.

Moghadam AR, da Silva Rosa SC, Samiei E, Alizadeh J, Field J, Kawalec P, Thliveris J, Akbari M, Ghavami S, Gordon JW.

Cell Death Discov. 2018 Oct 25;4:52. doi: 10.1038/s41420-018-0115-9. eCollection 2018. Erratum in: Cell Death Discov. 2019 Jul 10;5:116.

7.

The European challenges of funding orphan medicinal products.

Szegedi M, Zelei T, Arickx F, Bucsics A, Cohn-Zanchetta E, Fürst J, Kamusheva M, Kawalec P, Petrova G, Slaby J, Stawowczyk E, Vocelka M, Zechmeister-Koss I, Kaló Z, Molnár MJ.

Orphanet J Rare Dis. 2018 Nov 6;13(1):184. doi: 10.1186/s13023-018-0927-y.

8.

Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis.

Kawalec P, Holko P, Gawin M, Pilc A.

Arch Med Sci. 2018 Aug;14(5):1125-1136. doi: 10.5114/aoms.2018.77561. Epub 2018 Aug 13. Review.

9.

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries.

Kamusheva M, Manova M, Savova AT, Petrova GI, Mitov K, Harsányi A, Kaló Z, Márky K, Kawalec P, Angelovska B, Lakić D, Tesar T, Draganic P, Geitona M, Hatzikou M, Paveliu MS, Männik A.

Front Pharmacol. 2018 Jul 20;9:795. doi: 10.3389/fphar.2018.00795. eCollection 2018.

10.

Impact of Biologic Treatment of Crohn's Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland.

Holko P, Kawalec P, Pilc A.

Front Pharmacol. 2018 Jun 11;9:621. doi: 10.3389/fphar.2018.00621. eCollection 2018.

11.

Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.

Holko P, Kawalec P, Pilc A.

Pharmacoeconomics. 2018 Jul;36(7):853-865. doi: 10.1007/s40273-018-0653-2.

12.

Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland.

Kawalec P, Stawowczyk E.

Prz Gastroenterol. 2018;13(1):61-68. doi: 10.5114/pg.2018.74568. Epub 2018 Mar 26.

13.

Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.

Kawalec P, Tesar T, Vostalova L, Draganic P, Manova M, Savova A, Petrova G, Rugaja Z, Männik A, Sowada C, Stawowczyk E, Harsanyi A, Inotai A, Turcu-Stiolica A, Gulbinovič J, Pilc A.

Front Pharmacol. 2017 Dec 18;8:892. doi: 10.3389/fphar.2017.00892. eCollection 2017.

14.

European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.

Kawalec P, Śladowska K, Malinowska-Lipień I, Brzostek T, Kózka M.

Ther Clin Risk Manag. 2017 Dec 21;14:15-29. doi: 10.2147/TCRM.S138677. eCollection 2018. Review.

15.

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.

Kawalec P, Holko P, Moćko P, Pilc A.

Rheumatol Int. 2018 Feb;38(2):189-201. doi: 10.1007/s00296-017-3919-7. Epub 2017 Dec 28. Review.

16.

A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.

Stawowczyk E, Kawalec P.

Pharmacoeconomics. 2018 Apr;36(4):419-434. doi: 10.1007/s40273-017-0601-6. Review.

17.

Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012-2014: an analysis of nationwide databases.

Holko P, Kawalec P, Stawowczyk E.

Eur J Gastroenterol Hepatol. 2018 Apr;30(4):456-464. doi: 10.1097/MEG.0000000000001047.

PMID:
29256907
18.

Feasibility of predicting tumor motion using online data acquired during treatment and a generalized neural network optimized with offline patient tumor trajectories.

Teo TP, Ahmed SB, Kawalec P, Alayoubi N, Bruce N, Lyn E, Pistorius S.

Med Phys. 2018 Feb;45(2):830-845. doi: 10.1002/mp.12731. Epub 2018 Jan 12.

PMID:
29244902
19.

Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study.

Holko P, Kawalec P, Mossakowska M.

Eur J Gastroenterol Hepatol. 2018 Feb;30(2):174-180. doi: 10.1097/MEG.0000000000001031.

PMID:
29194233
20.

An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.

Kawalec P, Moćko P.

J Comp Eff Res. 2018 Feb;7(2):101-111. doi: 10.2217/cer-2017-0041. Epub 2017 Nov 8.

PMID:
29115855

Supplemental Content

Loading ...
Support Center